Summary
Following closely behind vildagliptin and sitagliptin, the two currently marketed compounds in the DPP-IV inhibitor drug class, are the pipeline agents saxagliptin and alogliptin. This article discusses data concerning all four molecules.
- endocrinology
- hyperglycemia/hypoglycemia
- diabetes mellitus
- © 2008 MD Conference Express
Tools
Table of contents
Cited By...
- No citing articles found.